Burning Rock Biotech Limited (BNR) 株式分析

企業概要

Burning Rock Biotech Limited (BNR) is a healthcare enterprise focused on the development and commercialization of cancer therapy selection tests, primarily serving markets within the People's Republic of China and the United States. The company operates within the broader Healthcare sector and specifically within the Diagnostics & Research industry, providing essential tools for oncology treatment planning. In terms of operational scale, the firm reports a market capitalization of $174.96M and generated annual revenue of $539.57M over the trailing twelve months, while the specific employee count is not disclosed in available filings. These valuation and revenue figures indicate that BNR holds a significant position in the diagnostic space, commanding a substantial market value despite currently reporting losses, which is characteristic of capital-intensive biotechnology firms investing heavily in research and development infrastructure.

財務健全性

The company reported a revenue of $539.57M for the trailing twelve months, yet the net income stands at -$55,346,000, revealing a substantial gap that highlights a heavy cost structure where operating expenses significantly exceed gross profits. Adjusted for non-cash items and other adjustments, the EBITDA is -$3,458,000, indicating that even before interest and taxes, the core business operations are currently generating negative cash earnings. The free cash flow is reported at -$41,697,876, which suggests that the company is consuming cash reserves to fund its growth initiatives and R&D efforts rather than generating surplus liquidity from operations. Analyzing the profitability margins, the gross margin is 74.7%, demonstrating high pricing power or low cost of goods sold relative to revenue, whereas the operating margin is -9.5% and the profit margin is -10.3%, both reflecting the high overhead costs typical of the biotech sector. Regarding liquidity and leverage, the company holds $478.39M in cash against $43.12M in debt, resulting in a debt-to-equity ratio of 8.06, which presents a leveraged balance sheet structure despite the high absolute cash balance. The current ratio stands at 2.99, indicating strong short-term liquidity and the ability to meet immediate obligations with nearly three times the current assets held. Finally, the return on equity is -9.9% and the return on assets is -4.0%, metrics that reveal that management is currently deploying capital to generate negative returns, a common phase for growth-stage companies prioritizing expansion over immediate profitability.

バリュエーション評価

The trailing twelve-month P/E ratio is not applicable due to negative earnings, while the forward P/E is listed at -28.02, implying that the market is pricing in future earnings recovery or that current valuation multiples are distorted by the loss-making status. The price-to-book ratio is 2.19, suggesting that the market values the company at more than twice its net asset book value, which often reflects intangible assets, proprietary technology, or growth potential not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.32 and the EV/EBITDA of -366.46 provide context, indicating that the stock is priced at a fraction of its sales, which is typical for pre-profitability biotech firms. In terms of price movement, the 52-week high is $41.72 and the 52-week low is $2.18, meaning the current trading price sits significantly below the recent peak, reflecting the volatility often associated with the sector. The beta value of 1.60 indicates that the stock's price volatility is substantially higher than the broader market, moving 60% more aggressively than the index in response to market fluctuations.

Growth & Income

The revenue growth year-over-year is 0.2%, while earnings growth is not applicable due to the negative net income, indicating that top-line growth is stagnant and not yet translating into improved profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are theoretically reinvested into the business or retained to cover losses rather than distributed to shareholders. Consequently, the company's income profile relies entirely on capital appreciation and operational turnaround rather than current income generation. The overall growth and income profile is characterized by flat revenue expansion and a complete absence of dividend distributions, positioning the asset as a pure growth play dependent on future clinical successes or commercial breakthroughs to shift its financial trajectory.